Skip to main content
Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.4445
-0.0011 (-0.25%)
At close: Nov 11, 2026, 4:00 PM EST
0.4599
+0.0154 (3.46%)
Pre-market: Nov 12, 2026, 8:14 AM EST

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
00.291.50.58--
Revenue Growth
-99.32%-80.98%157.63%---
Cost of Revenue
7.047.049.367.6316.423.9
Gross Profit
-7.04-6.76-7.86-7.04-16.4-23.9
Selling, General & Admin
6.866.486.468.4320.9713.55
Research & Development
1.38-----
Operating Expenses
8.246.486.468.4320.9713.55
Operating Income
-15.28-13.23-14.32-15.47-37.37-37.45
Interest & Investment Income
0.970.651.291.220.450
Currency Exchange Gain (Loss)
0-0.10.07-0.040.280.32
Other Non Operating Income (Expenses)
0.160.08----
EBT Excluding Unusual Items
-14.14-12.6-12.96-14.29-36.64-37.13
Pretax Income
-14.14-12.6-12.96-14.29-112.66-37.13
Net Income
-14.14-12.6-12.96-14.29-112.66-37.13
Net Income to Common
-14.14-12.6-12.96-14.29-112.66-37.13
Net Income Growth
------
Shares Outstanding (Basic)
3276421
Shares Outstanding (Diluted)
3276421
Shares Change
432.43%18.67%52.31%118.31%55.69%0.72%
EPS (Basic)
-0.44-1.93-2.35-3.95-67.99-34.88
EPS (Diluted)
-0.44-1.93-2.35-3.95-67.99-34.88
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-12.74-12.89-13.57-12.27-25.01-37.69
Free Cash Flow Per Share
-0.39-1.97-2.46-3.39-15.09-35.41
Operating Margin
-457872.76%-4631.12%-953.00%-2652.80%--
Profit Margin
-423878.66%-4409.16%-862.43%-2449.59%--
Free Cash Flow Margin
-381769.10%-4512.35%-903.26%-2103.92%--
EBITDA
-15.26-13.21-14.3-15.46-37.37-37.43
D&A For EBITDA
0.020.020.020.0100.01
EBIT
-15.28-13.23-14.32-15.47-37.37-37.45
SEC Filings: 10-K · 10-Q